TY  - JOUR
AU  - Moreno-Arribas, José
AU  - Bertomeu-González, Vicente
AU  - Anguita-Sanchez, Manuel
AU  - Cequier, Ángel
AU  - Muñiz, Javier
AU  - Castillo, Jesús
AU  - Sanchis, Juan
AU  - Roldán, Inmaculada
AU  - Marín, Francisco
AU  - Bertomeu-Martínez, Vicente
AU  - investigators of the FANTASIIA study
PY  - 2015
DO  - 10.1177/1074248415596426
UR  - http://hdl.handle.net/10668/10027
T2  - Journal of cardiovascular pharmacology and therapeutics
AB  - Atrial fibrillation (AF) is associated with an increased risk of thromboembolic events. Many patients with AF receive chronic anticoagulation, either with vitamin K antagonists (VKAs) or with non-VKA oral anticoagulants (NOACs). We sought to analyze...
LA  - en
KW  - anticoagulant treatment
KW  - atrial fibrillation
KW  - nonvitamin K antagonist oral anticoagulants
KW  - vitamin K antagonists
KW  - Administration, Oral
KW  - Aged
KW  - Aged, 80 and over
KW  - Anticoagulants
KW  - Atrial Fibrillation
KW  - Clinical Decision-Making
KW  - Female
KW  - Fibrinolytic Agents
KW  - Hemorrhage
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Vitamin K
TI  - Choice of New Oral Anticoagulant Agents Versus Vitamin K Antagonists in Atrial Fibrillation: FANTASIIA Study.
TY  - research article
VL  - 21
ER  -